Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 02.06.2026. Verfasst von Consuelo Torrini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Krantz Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Human Genome Research Institute, National Institute of Health, American Association for Cancer Research, Krantz Breakthrough Grant.
Abstract (Originalsprache)
Background
Despite advances in treatment, brain metastasis (BM) management remains a significant challenge. Adagrasib is a brain-penetrant KRASG12C inhibitor active in patients with BM. KRAS mutations are linked with immune escape and may contribute to the limited clinical benefit from single-agent immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 in BM. Although adagrasib sensitizes extracranial tumors to ICI, its intracranial benefit combined with immunotherapy remains unknown. Here, we evaluate adagrasib with ICI in mouse models that mimic the BM immune microenvironment.
Methods
We tested the in vitro efficacy of adagrasib on two KrasG12C-mutant murine cancer cells: colorectal CT26G12C and lung cancer KPARG12C. Murine BM models resembling the immunologic characteristics of BM were established by subcutaneous and intracranial injection of these cells. Animals were treated with adagrasib combined with anti-PD-1 and monitored for intracranial tumor growth and survival. Disease-free mice after 11-13 weeks were rechallenged with a higher tumor cell dose to assess tumor-specific memory.
Results
Three-week adagrasib monotherapy and combination therapy with ICI demonstrated benefit in colorectal and lung cancer BM models. Adagrasib alone and in combination demonstrated similarly potent anti-tumor effects against extracranial tumors. While monotherapies reduced intracranial tumor growth, adagrasib with ICI showed the most favorable outcome. Although both adagrasib monotherapy and combination therapy extended survival, long-term intracranial disease control after rechallenge was the greatest with combination therapy.
Conclusions
Adagrasib with ICI improved long-term survival and blocked CNS progression in dual extra- and intracranial BM models. These findings support investigation of adagrasib with ICI in patients with KRASG12C-mutant BM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Krantz Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Mirati Therapeutics, Inc., A Bristol Myers Squibb Company, San Diego, California, USA.
- Divisions of Hematology/Oncology and Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Consuelo Torrini, Hiroaki Wakimoto, Priscilla K Brastianos
Förderung
- National Human Genome Research Institute
- National Institute of Health
- American Association for Cancer Research, Krantz Breakthrough Grant
- Terry and Jean de Gunzburg MGH Research Scholar
- Breast Cancer Research Foundation
- National Brain Tumor Society
- Hellenic Women’s Club
- Melanoma Research Alliance
Zitieren
APA
Torrini, C., Nayyar, N., Wojtkiewicz, G. R., Giobbie-Hurder, A., de Sauvage, M. A., Migliarese, C., Summers, E. J., Ijad, N., Yamazawa, E., Zhang, B. S., Sullivan, E. M., Sasisekharan, V., Richardson, L. G., Marion, B. M., Olson, P., Wakimoto, H., & Brastianos, P. K. (2026). Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag107
Vancouver
Torrini C, Nayyar N, Wojtkiewicz GR, Giobbie-Hurder A, de Sauvage MA, Migliarese C, et al. Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag107
BibTeX
@article{Torrini2026,
author = {Torrini, Consuelo and Nayyar, Naema and Wojtkiewicz, Gregory R and Giobbie-Hurder, Anita and de Sauvage, Magali A and Migliarese, Christian and Summers, Elizabeth J and Ijad, Nazanin and Yamazawa, Erika and Zhang, Britney S and Sullivan, Emily M and Sasisekharan, Varun and Richardson, Leland G and Marion, Braxton M and Olson, Peter and Wakimoto, Hiroaki and Brastianos, Priscilla K},
title = {Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag107}
}
EUVIMED